Other companies developing claudin 18.2-targeted therapies include Innovent, which started dosing patients with its IBI343 antibody in a phase 1 trial involving patients with various solid tumours ...

The EU has followed Japan and GB in approving Astellas' first-to-market claudin 18.2-targeted therapy Vyloy, clearing it for gastric and gastroesophageal junction (GEJ) cancer. Vyloy (zolbetuximab ...

The Gastric Cancer Registry: A multi-omic cellular and molecular resource for cancer biomarker and therapeutic discovery. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers ...

2025年1月6日，中山大学肿瘤防治中心徐瑞华教授团队在国际权威肿瘤学期刊《柳叶刀·肿瘤》（The Lancet Oncology）上公布了一项具有里程碑意义的临床研究：靶向Claudin 18.2的抗体偶联药物（CMG901 ...

Claudin is a protein family that contains at ... which are important for signal transduction and cell polarity. Claudin18.2, a known subtype of Claudin18, is weakly expressed in differentiated ...

Xilio Therapeutics Inc. has announced three wholly owned preclinical programs for masked T-cell engagers targeting prostate-specific membrane antigen (PSMA), claudin 18.2 (CLDN18.2) and ...

Peak part 1 summary: A phase 3, randomized, open-label, multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal ...

Xilio Therapeutics (XLO) announced three wholly-owned preclinical programs for masked T cell engagers targeting prostate-specific membrane ...

Suggested remit: To appraise the clinical and cost effectiveness of Zolbetuximab with nab-paclitaxel and gemcitabine within its marketing authorisation for treating pancreatic cancer.